A seven-gene signature predicts overall survival of patients with colorectal cancer

Colorectal cancer (CRC) is a major cause of global cancer mortality. Gene expression profiles can help predict prognosis of patients with CRC. In most of previous studies, disease recurrence was analyzed as the survival endpoint. Thus we aim to build a robust gene signature for prediction of overall survival (OS) in patients with CRC. Fresh frozen CRC tissues from 64 patients were analyzed using Affymetrix HG-U133plus 2.0 gene arrays. By performing univariate survival analysis, 6487 genes were found to be associated with the OS in our cohort. KEGG analysis revealed that these genes were mainly involved in pathways such as endocytosis, axon guidance, spliceosome, Wnt signalling and ubiquitin mediated proteolysis. A seven-gene signature was further selected by a robust likelihood-based survival modelling approach. The prognostic model of seven-gene signature (NHLRC3, ZDHHC21, PRR14L, CCBL1, PTPRB, PNPO, and PPIP5K2) was constructed and weighted by regression coefficient, which divided patients into high- and low-risk groups. The OS for patients in high-risk group was significantly poorer compared with patients in low-risk group. Moreover, all seven genes were found to be differentially expressed in CRC tissues as compared with adjacent normal tissues, indicating their potential role in CRC initiation and progression. This seven-gene signature was further validated as an independent prognostic marker for OS prediction in patients with CRC in other two independent cohorts. In short, we developed a robust seven-gene signature that can predict the OS for CRC patients, providing new insights into identification of CRC patients with high risk of mortality.

[1]  A. Sparks,et al.  Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. , 1998, Cancer research.

[2]  Daniela M. Witten,et al.  An Introduction to Statistical Learning: with Applications in R , 2013 .

[3]  L. V. van't Veer,et al.  Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Jemal,et al.  Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.

[5]  X. Xing,et al.  The prognostic value of CDKN2A hypermethylation in colorectal cancer: a meta-analysis , 2013, British Journal of Cancer.

[6]  M. Salto‐Tellez,et al.  EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer , 2015, Clinical Cancer Research.

[7]  D. Kerr,et al.  Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study , 2007, The Lancet.

[8]  Bert Vogelstein,et al.  Mutational Analysis of the APC/β-Catenin/Tcf Pathway in Colorectal Cancer , 1998 .

[9]  N. Kasabov,et al.  Multiple Gene Expression Classifiers from Different Array Platforms Predict Poor Prognosis of Colorectal Cancer , 2007, Clinical Cancer Research.

[10]  J. Ajani,et al.  Adjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal Oncology. , 2007, Gastrointestinal cancer research : GCR.

[11]  M. Pino,et al.  The chromosomal instability pathway in colon cancer. , 2010, Gastroenterology.

[12]  Y. Nakamura,et al.  Clinical and pathological associations with allelic loss in colorectal carcinoma [corrected]. , 1989, JAMA.

[13]  I. Yang,et al.  Molecular staging for survival prediction of colorectal cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Syljuåsen,et al.  The role of the ubiquitin/proteasome system in cellular responses to radiation , 2003, Oncogene.

[15]  Jaewoo Kang,et al.  Robust Likelihood-Based Survival Modeling with Microarray Data , 2009 .

[16]  M. Somerfield,et al.  American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Elizabeth M Webber,et al.  Oncotype DX tumor gene expression profiling in stage II colon cancer , 2010, PLoS currents.

[18]  G. Orphanides,et al.  Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines , 2012, BMC Medical Genomics.

[19]  I. Tan,et al.  Genetics: An 18-gene signature (ColoPrint®) for colon cancer prognosis , 2011, Nature Reviews Clinical Oncology.

[20]  I. Frayling,et al.  Systematic review of genetic influences on the prognosis of colorectal cancer , 2004, The British journal of surgery.

[21]  Shung-Haur Yang,et al.  Analysis of the seventh edition of American Joint Committee on colon cancer staging , 2012, International Journal of Colorectal Disease.

[22]  Debashis Sahoo,et al.  CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. , 2016, The New England journal of medicine.

[23]  M. Salto‐Tellez,et al.  EphA 2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer , 2015 .

[24]  D. Sahoo,et al.  CDX 2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer , 2016 .

[25]  Lewis C Cantley,et al.  A colorectal cancer classification system that associates cellular phenotype and responses to therapy , 2013, Nature Medicine.

[26]  John Quackenbush.  Microarray analysis and tumor classification. , 2006, The New England journal of medicine.

[27]  M. Washington,et al.  PIK3CA and APC mutations are synergistic in the development of intestinal cancers , 2014, Oncogene.

[28]  R. Moon,et al.  WNT signalling pathways as therapeutic targets in cancer , 2012, Nature Reviews Cancer.

[29]  K. Zou,et al.  Receiver-Operating Characteristic Analysis for Evaluating Diagnostic Tests and Predictive Models , 2007, Circulation.

[30]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[31]  C. Hellberg,et al.  Protein-tyrosine phosphatases and cancer , 2006, Nature Reviews Cancer.

[32]  Ying Yuan,et al.  Secreted Protein Acidic and Rich in Cysteines-like 1 Suppresses Aggressiveness and Predicts Better Survival in Colorectal Cancers , 2012, Clinical Cancer Research.

[33]  D. Matos,et al.  Genetic and Immunohistochemical Expression of Integrins ITGAV, ITGA6, and ITGA3 As Prognostic Factor for Colorectal Cancer: Models for Global and Disease-Free Survival , 2015, PloS one.

[34]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  T. Yeatman,et al.  Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. , 2010, Gastroenterology.

[36]  B. Vogelstein,et al.  p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. , 1990, Cancer research.

[37]  M. Barbacid,et al.  RAS oncogenes: the first 30 years , 2003, Nature Reviews Cancer.

[38]  O. Hoekstra,et al.  Glucose Transporter 1 (SLC2A1) and Vascular Endothelial Growth Factor A (VEGFA) Predict Survival After Resection of Colorectal Cancer Liver Metastasis. , 2016, Annals of surgery.

[39]  Ju-Seog Lee,et al.  CRC-113 gene expression signature for predicting prognosis in patients with colorectal cancer , 2015, Oncotarget.

[40]  T. Ørntoft,et al.  Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer , 2009, Clinical Cancer Research.

[41]  Yingdong Zhao,et al.  Analysis of Gene Expression Data Using BRB-Array Tools , 2007, Cancer informatics.